Category: NewsThe default category.
The default category.

Evaluating the value of supportive medical apps during the treatment for breast cancer
Young-Afat et al, 2014; Amsterdam EBCC9.

First place in the Digital Health Masterclass Challenge 2013
Px HealthCare won first place in the Digital Health Masterclass Challenge held by Janssen Healthcare Innovation and Johnson & Johnson Innovation.
Px HealthCare
Our mission is to revolutionise the use of the patient’s voice to improve both patient experience and clinical outcomes in cancer.

NHS Innovation Accelerator
Anne joined the NHS Innovation Accelerator (NIA) from the Netherlands … Continue reading “NHS Innovation Accelerator”

Optimising oncology outcomes with a mobile app for breast cancer patients: A qualitative evaluation.
2016 NCRI Conference

Is there value in using patient recorded outcome measures to improve toxicity management patients receiving chemotherapy for breast cancer?
2017 Annual British Oncology Pharmacy Association Symposium

Px HealthCare Presents Comparative Regional Evaluation of OWise Breast Cancer Patient Support App
A comparative evaluation of OWise breast cancer app use in the UK and the Netherlands. UK users, reached through OWise social media campaigns, spent longer per session and contributed more patient-reported outcome data. Presented at IPOS 2024, Maastricht.

Px HealthCare Unveils First-of-its-Kind, Real World Evidence Study Using OWise Breast Cancer Patient Support App
A UK nationwide real-world observational study on the OWise platform, designed to capture longitudinal patient-reported outcomes in routine NHS care. HRA and REC approved, and presented at SABCS 2023.

OWise receives top prize in Scotland’s Cancer Innovation Challenge
OWise was one of the projects selected to win the finals and progress to phase two of the Cancer Innovation Challenge!

OWise wins top NESTA Healthier Lives Data Fund Prize
Px Healthcare won £60,000 in funding from the Scottish Government to keep developing their products and scale them across Scotland.

